The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms

  • Rainald Mössner
  • Anna Schuhmacher
  • Michael Wagner
  • Leonhard Lennertz
  • Anja Steinbrecher
  • Boris B. Quednow
  • Dan Rujescu
  • Marcella Rietschel
  • Wolfgang Maier
Original Paper

DOI: 10.1007/s00406-011-0235-1

Cite this article as:
Mössner, R., Schuhmacher, A., Wagner, M. et al. Eur Arch Psychiatry Clin Neurosci (2012) 262: 193. doi:10.1007/s00406-011-0235-1

Abstract

Genetic factors determining the response to antipsychotic treatment in schizophrenia are poorly understood. A new schizophrenia susceptibility gene, the zinc-finger gene ZNF804A, has recently been identified. To assess the pharmacogenetic importance of this gene, we treated 144 schizophrenia patients and assessed the response of positive and negative symptoms by PANSS. Patients homozygous for the ZNF804A risk allele for schizophrenia (rs1344706 AA) showed poorer improvement of positive symptoms (7.35 ± 0.46) compared to patients with a protective allele (9.41 ± 0.71, P = 0.022). This provides further evidence that ZNF804A is of functional relevance to schizophrenia and indicates that ZNF804A may be a novel target for pharmacological interventions.

Keywords

Schizophrenia Pharmacogenetics Positive symptoms 

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Rainald Mössner
    • 1
  • Anna Schuhmacher
    • 1
  • Michael Wagner
    • 1
  • Leonhard Lennertz
    • 1
  • Anja Steinbrecher
    • 1
  • Boris B. Quednow
    • 1
    • 2
  • Dan Rujescu
    • 3
  • Marcella Rietschel
    • 5
  • Wolfgang Maier
    • 1
  1. 1.Department of Psychiatry and PsychotherapyUniversity of BonnBonnGermany
  2. 2.University Hospital of Psychiatry, University of ZurichZurichSwitzerland
  3. 3.University of MunichMunichGermany
  4. 4.Department of Psychiatry and PsychotherapyUniversity of MunichMunichGermany
  5. 5.Central Institute of Mental HealthMannheimGermany

Personalised recommendations